ANIP Ani Pharmaceuticals Earnings and EPS analysis

Relative Growth: Rel. Growth: 91

Relative Strength: Rel. Strength: 50

Relative Valuation: Rel. Valuation: 87

Relative Profitability: Rel. Profitability: 91

EPS in 2026 (TTM): $4.11

Last Report Period Date: Mar 31, 2026

As of June 2026, according to Ani Pharmaceuticals's latest financial report, the company's current EPS (TTM) is $4.11. In 2025, the company recorded an earnings per share (EPS) of $3.5, which represents an increase compared to its EPS of -$1.04 in 2024. Ani Pharmaceuticals's earnings per share for the quarterly report ending on Mar 31, 2026 was $1.31.

ANIP earnings history

Historical annual and quarterly earnings per share (EPS) data for Ani Pharmaceuticals

EPS (TTM)

$4.11

EPS Growth YoY (Quarterly)

87.1%

EPS (Quarterly)

$1.31

EPS Growth (Quarterly)

5.6%

The annual EPS in 2025 was $3.5, an increase of 436.5% from -$1.04 in 2024. For the quarter ending Mar 31, 2026, the EPS was $1.31, showing a 87.1% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $4.11. In 2024, the annual EPS was -$1.04, showing a decrease of 220.9% from 2023.

ANIP earnings chart

ANIP EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

87.1%

EPS growth YoY

436.5%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the last 12 months, Ani Pharmaceuticals has registered an EPS growth of 87.1% (YoY, quarterly). A 10-year view shows that ANIP has seen an average EPS growth of 10.1% per year.

ANIP Earnings Waterfall

Breakdown of revenue, profit and net income for Ani Pharmaceuticals

ANIP Earnings vs Peers

What are the earnings of ANIP compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
PFE Pfizer Inc	18.89	-3.5%	-37.4%	-3.7%
ANIP Ani Pharmaceuticals Inc	20.17	436.5%	N/A	N/A
NVS Novartis AG	21.85	21.8%	31.2%	15.2%
TEVA Teva Pharmaceutical Industries Ltd	24.15	184.8%	N/A	N/A
RPRX Royalty Pharma plc	28.98	-6.8%	161.6%	6.3%
CAH Cardinal Health Inc	34.16	86.2%	N/A	N/A
JAZZ Jazz Pharmaceuticals plc	490.26	-164.5%	N/A	N/A
CLDX Celldex Therapeutics Inc	N/A	-59.2%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.